Literature DB >> 31213431

Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.

John Y Rhee1, Douglas Tremblay2, Amy M Chan3, Martin S Tallman4, John Mascarenhas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31213431      PMCID： PMC6595259          DOI： 10.1182/bloodadvances.2019000249

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  13 in total

1.  Acute arsenic poisoning.

Authors:  Antonio Dueñas-Laita; Manuel Pérez-Miranda; María A González-López; Juan C Martín-Escudero; Marta Ruiz-Mambrilla; Jesús Blanco-Varela
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

2.  Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.

Authors:  Wing-Yan Au; Sidney Tam; Bonnie M Fong; Yok-Lam Kwong
Journal:  Blood       Date:  2006-04-01       Impact factor: 22.113

3.  Acute arsenic treatment alters arachidonic acid and its associated metabolite levels in the brain of C57Bl/6 mice.

Authors:  Anwar Anwar-Mohamed; Osama H Elshenawy; Ahmed A El-Sherbeni; Mohamed Abdelrady; Ayman O S El-Kadi
Journal:  Can J Physiol Pharmacol       Date:  2014-08       Impact factor: 2.273

4.  Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Authors:  Michael H Skinner; Han-Yi Kuan; Alan Pan; Korbtham Sathirakul; Mary Pat Knadler; Celedon R Gonzales; Kwee Poo Yeo; Shobha Reddy; Maggie Lim; Mosun Ayan-Oshodi; Stephen D Wise
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

5.  Impact of early developmental arsenic exposure on promotor CpG-island methylation of genes involved in neuronal plasticity.

Authors:  Liborio Martínez; Verónica Jiménez; Christian García-Sepúlveda; Fátima Ceballos; Juan Manuel Delgado; Perla Niño-Moreno; Lesly Doniz; Víctor Saavedra-Alanís; Claudia G Castillo; Martha E Santoyo; Roberto González-Amaro; María E Jiménez-Capdeville
Journal:  Neurochem Int       Date:  2011-02-15       Impact factor: 3.921

6.  Chronic exposure to low levels of inorganic arsenic causes alterations in locomotor activity and in the expression of dopaminergic and antioxidant systems in the albino rat.

Authors:  Verónica Mireya Rodríguez; Jorge Humberto Limón-Pacheco; Leticia Carrizales; María Soledad Mendoza-Trejo; Magda Giordano
Journal:  Neurotoxicol Teratol       Date:  2010-08-10       Impact factor: 3.763

7.  Attenuation of arsenic neurotoxicity by curcumin in rats.

Authors:  Rajesh S Yadav; Madhu Lata Sankhwar; Rajendra K Shukla; Ramesh Chandra; Aditya B Pant; Fakhrul Islam; Vinay K Khanna
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-23       Impact factor: 4.219

8.  Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.

Authors:  Sabine Knipp; Norbert Gattermann; Marc Schapira; Herbert Käferstein; Ulrich Germing
Journal:  Leuk Res       Date:  2007-04-09       Impact factor: 3.156

9.  Genome-wide alteration of histone H3K9 acetylation pattern in mouse offspring prenatally exposed to arsenic.

Authors:  Andrea A Cronican; Nicholas F Fitz; Alexis Carter; Muzamil Saleem; Sruti Shiva; Aaron Barchowsky; Radosveta Koldamova; Jonathan Schug; Iliya Lefterov
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

10.  Incident adverse events following therapy for acute promyelocytic leukemia.

Authors:  Peter Geon Kim; Kelly Bridgham; Evan C Chen; Mahesh K Vidula; Olga Pozdnyakova; Andrew M Brunner; Amir T Fathi
Journal:  Leuk Res Rep       Date:  2018-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.